Your session is about to expire
← Back to Search
Other
APL-1401 for Ulcerative Colitis
Verified Trial
Phase 1
Recruiting
Research Sponsored by Jiangsu Yahong Meditech Co., Ltd aka Asieris
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Are you between 18-65 years of age?
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 through day 28
Summary
This trial tests a new drug, APL-1401, taken daily by mouth, on patients with severe Ulcerative Colitis. It aims to find the safest and most effective dose over a few weeks.
Who is the study for?
Adults aged 18-65 with moderately to severely active Ulcerative Colitis (UC) can join this trial. They must have a UC diagnosis for at least 3 months, a Total Mayo Score of 6-12, and be on stable doses of certain medications. Women must test negative for pregnancy and use two birth control methods; men also need to follow specific contraception guidelines.
What is being tested?
APL-1401 is being tested against a placebo in this study. Participants will randomly receive either the drug or placebo without knowing which one they're getting. The trial includes initial screening, treatment over four weeks, and follows up safety checks until day 58.
What are the potential side effects?
While the side effects of APL-1401 are not detailed here, typical side effects in such trials may include digestive issues like nausea or diarrhea, potential allergic reactions, fatigue, headaches, and possibly increased risk of infection.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 65 years old.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1 through day 28
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 through day 28
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants adverse events (AEs)
Number of Participants adverse events of special interest (AESI)
Number of Participants serious adverse events (SAEs)
Secondary study objectives
AUC
AUC0-24
AUClast
+11 moreOther study objectives
CRP
ESR
Fecal calprotectin
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: APL-1401Experimental Treatment1 Intervention
On Day 1, patients will be randomized to receive either APL-1401 or placebo in a 5:1 ratio. Patients will receive APL-1401 orally once daily (QD) during the 28-day treatment period.
Group II: PlaceboPlacebo Group1 Intervention
Identically matching placebo capsules once daily for 28 days
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Ulcerative Colitis (UC) include immunomodulators and anti-inflammatory agents. Immunomodulators, such as azathioprine and 6-mercaptopurine, work by altering the immune system's activity to reduce inflammation and prevent flare-ups.
Anti-inflammatory agents, like mesalamine and corticosteroids, directly reduce inflammation in the colon. These treatments are crucial for UC patients as they help manage symptoms, maintain remission, and improve quality of life by controlling the chronic inflammation that characterizes the disease.
Emerging Therapies for Inflammatory Bowel Diseases.
Emerging Therapies for Inflammatory Bowel Diseases.
Find a Location
Who is running the clinical trial?
Jiangsu Yahong Meditech Co., Ltd aka AsierisLead Sponsor
6 Previous Clinical Trials
1,485 Total Patients Enrolled
Qiuyue QUStudy DirectorJiangsu Yahong Meditech Co., Ltd aka Asieris
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't used topical 5-ASA or steroids like enemas or suppositories in the last 2 weeks.I have not taken JAK inhibitors like tofacitinib or upadacitinib in the last 4 weeks.I am between 18 and 65 years old.I have not taken intravenous corticosteroids in the week before joining.I haven't taken drugs like ustekinumab in the last 14 weeks.
Research Study Groups:
This trial has the following groups:- Group 1: APL-1401
- Group 2: Placebo
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.